Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Therapies in Moderate to Severe Crohn's Disease
NCT06548542Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Primary completion
- Jan 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 33
01
Overview
A Phase 2 trial of risankizumab, livmoniplimab, lutikizumab, ABBV-8736 in Crohn's disease, sponsored by AbbVie Inc.. Started Sep 2024; status: recruiting.
02
Drugs
risankizumablivmoniplimablutikizumabABBV-8736
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06548542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548542.